Il percorso diagnostico-assistenziale della broncopneumopatia cronica ostruttiva riacutizzata in Medicina Interna

Chronic obstructive pulmonary disease pathways as a tool to improve appropriateness in Internal Medicine Departments

“…With regard to bronchodilator therapy, although there are no controlled studies, there is great consensus on the choice of shortacting bronchodilators, b2-agonist (SABA) and/or short acting muscarinic antagonists (SAMA). [9][10][11][12][13][14][15][16][17]22,23 The administration of short-acting bronchodilators must be of intensive type, every 5-6 h, because their duration of action, in particular for SABA, is only 4-6 h.…”